Eli Lilly and Company (NYSE:LLY) EVP Sells $5,950,000.00 in Stock

Eli Lilly and Company (NYSE:LLY) EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,219.57 on Thursday. Eli Lilly and Company has a 1 year low of $644.50 and a 1 year high of $1,249.45. The company’s 50 day simple moving average is $1,168.12 and its 200 day simple moving average is $1,050.82. The company has a market capitalization of $1.15 trillion, a price-to-earnings ratio of 40.93, a PEG ratio of 1.43 and a beta of 0.51. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. During the same period in the previous year, the company earned $6.31 EPS. Eli Lilly and Company’s revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 36.33 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is presently 23.22%.

Institutional Trading of Eli Lilly and Company

A number of institutional investors and hedge funds have recently bought and sold shares of LLY. Brighton Jones LLC lifted its holdings in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC raised its position in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares during the period. Schnieders Capital Management LLC. raised its position in Eli Lilly and Company by 16.7% in the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after purchasing an additional 1,141 shares during the period. Flow Traders U.S. LLC acquired a new position in shares of Eli Lilly and Company during the second quarter worth about $356,000. Finally, Nebula Research & Development LLC acquired a new position in shares of Eli Lilly and Company during the second quarter worth about $749,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly filed six lawsuits against U.S. companies accused of selling unauthorized versions of experimental obesity drug retatrutide and has referred more than 200 alleged sellers to regulators. The crackdown could help protect the drug’s brand, future pricing power and potential commercial launch ahead of a regulatory filing. Lilly sues six companies over retatrutide sales
• Positive Sentiment: Lilly’s oral GLP-1 weight-loss treatment Foundayo received its first approval outside the United States in the U.K. The decision expands Lilly’s international obesity franchise and could increase access to a more convenient pill-based treatment, although initial availability will primarily be through private prescriptions. Foundayo receives U.K. approval
• Positive Sentiment: Lilly’s $40 million strategic investment in Absci, linked to development of antibody candidate ABS-201, gives the company additional pipeline exposure and strengthens its drug-discovery partnerships. The deal is unlikely to materially affect near-term earnings but supports Lilly’s longer-term innovation strategy. Absci reports Lilly investment
• Neutral Sentiment: Novo Nordisk’s CEO defended the company’s lawsuit alleging unfair advertising by Lilly. The dispute adds competitive and legal uncertainty to the GLP-1 market, but the immediate financial impact on Lilly remains unclear. Novo Nordisk defends lawsuit against Lilly
• Negative Sentiment: The retatrutide litigation could also highlight regulatory, safety and reputational risks before the drug is approved. Legal expenses and uncertainty over unauthorized competing products may weigh on sentiment despite the lawsuits’ potential protective benefits. Lilly files retatrutide lawsuits

Wall Street Analyst Weigh In

A number of research firms have recently commented on LLY. BMO Capital Markets reaffirmed an “outperform” rating and set a $1,400.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, August 6th. Cantor Fitzgerald boosted their target price on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Citigroup upped their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. JPMorgan Chase & Co. increased their price target on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 7th. Finally, Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $1,292.18.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.